Peptide treatments sit at the centre of metabolic, longevity, and aesthetic medicine, and UAE demand is real. So is the regulation around it. This guide sets out how to start a peptide business in the UAE legally: the licensed structure, the sequence to follow, and a realistic timeline to a first prescription.
What a legal peptide business looks like in the UAE
A peptide business in the UAE is not an online shop that ships vials. It is a licensed clinical operation with a regulated supply chain behind it. Every compliant version of the model is built from three licensed layers working together, and each layer answers to a different authority.
The three licensed layers
- A DHA-licensed telehealth operation as the clinical front end, where licensed clinicians consult and prescribe
- MOHAP-licensed compounding pharmacy partners preparing compounded medicines against individual prescriptions
- A registered supply chain: EDE classification, registrations where required, import permits, cold chain, and licensed distribution
The patient sees a brand, a consultation, and a delivery. The regulators see a DHA facility licence, licensed prescribers, a MOHAP-licensed pharmacy, and a permit trail behind every product. Operators who win in this market are the ones who build that structure properly, because in the UAE the structure is the business.
Step one is always EDE classification
Before any product is offered, the Emirates Drug Establishment (EDE) decides what it is. The EDE classifies each peptide product case by case: as a biological medicinal product, as a conventional pharmaceutical, or as not eligible for registration. There is no blanket rule for peptides as a category, and a decision on one product does not transfer to another.
Classification comes first because it fixes everything downstream: the registration route, the evidence expectations, and the import permits your supply chain will need. It is also where the legal risk lives. Importation outside the registered pathway risks seizure and penalties, so a serious operator confirms the pathway per product before marketing anything. A treatment menu is a classification exercise before it is a commercial one.
The telehealth front end: DHA, Sheryan, NABIDH
The clinical front end in Dubai runs on a DHA telehealth facility licence, applied for through the Sheryan portal. Consultations are delivered by DHA-licensed clinicians under the DHA Telehealth Standards, and every encounter is documented in an EMR connected to NABIDH, the DHA health information exchange.
The rule that shapes the whole model is simple: a consultation comes before every prescription. The storefront presents treatment categories and routes visitors into a consultation; the licensed clinician holds the prescribing decision on every case. Nothing is sold directly, and prescription-only medicines move only on a clinician's prescription. The full front end, entity, licence, premises, clinical team, and EMR, is the same build we describe on our telemedicine business setup page.
Compounding and supply
Behind the clinical layer sits the pharmaceutical one. Compounded peptide preparations are made by licensed compounding pharmacies, against prescriptions from licensed clinicians, for individual patients. Compounding pharmacy licensing sits with MOHAP, which retained it under the current law, so the correct structure is a DHA-licensed telehealth operation in front with MOHAP-licensed compounding pharmacy partners behind it. You do not need to own a pharmacy to launch; you need the right partners under the right agreements.
Supply is the other half. Peptides are temperature sensitive, so the chain behind the pharmacies runs on licensed importation under our own importer credentials, EDE import permits, a GDP medical warehouse, cold chain transport, and licensed distribution to the point of dispensing. Where a product requires registration, we act as the Marketing Authorisation Holder. Every link in that chain is licensed, which is what keeps the model durable when authorities look at it closely.
The turnkey build and timeline
Built as one engagement, the sequence from concept to first prescription looks like this.
Scope and fixed quote
You tell us the treatments you want to offer. We respond within 48 hours with the legal pathway per product, the build plan, and one fixed, all-inclusive quote.
Entity and DHA licence
Company formation, compliant premises, and the DHA telehealth facility application through Sheryan.
Clinical team and policies
The Medical Director and clinicians are licensed, telehealth policies are written, and the NABIDH-connected EMR is stood up.
Supply chain
Classification files per product, compounding pharmacy partner arrangements, import permits, and the cold chain route.
Launch and fulfilment
First consultations, first prescriptions, and fulfilment through licensed channels from day one.
A build typically reaches an active DHA licence in approximately 45 to 60 days, subject to authority response times, with the supply chain workstream run in parallel so the clinical and pharmaceutical layers arrive together. The full structure, and what one engagement covers, is on our peptide business in the UAE page.
Explore the peptide business build
Frequently asked questions
Is a peptide business legal in the UAE?
Do I need my own compounding pharmacy to start?
Can I offer BPC-157 or GLP-1 treatments?
How long until a peptide business can launch in the UAE?
This guide is general information for operators and investors, not medical, legal, or regulatory advice. Peptide products are classified by the EDE case by case, and prescription medicines are prescribed only by licensed clinicians after consultation. Confirm current rules with the relevant authority or your regulatory partner before acting.